Skip to main content

Acute Myeloid Leukemia


True or False: First-line enasidenib demonstrates worse efficacy in the real-world setting than in clinical trials for the treatment of relapsed/refractory IDH2-mutated AML.
Amer Zeidan, MBBS, MHS, discusses results from a retrospective study examining FLT3 testing trends, treatment patterns…
Integrated palliative and oncology care for patients with AML improves QoL, psychological stress, and end-of-life care…
Andrew Klink, PhD, MPH, discusses results from a real-world cohort study confirming the effectiveness of enasidenib for…
Conference Coverage
Results from a real-world study confirm the effectiveness of first-line enasidenib therapy for patients with relapsed/…
Back to Top